{"DataElement":{"publicId":"7067852","version":"1","preferredName":"Amyloidosis Disorder Best Response Outcome Status","preferredDefinition":"The status of the best response to Amyloidosis.","longName":"AMD_DIS_BES_RSPNS_ST","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"7067843","version":"1","preferredName":"Amyloidosis Disease or Disorder Best Response Outcome","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._The result of an action.","longName":"3003939v1.0:7067841v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3003939","version":"1","preferredName":"Amyloidosis","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.","longName":"C2868","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E2F4315-122C-5E22-E040-BB89AD43496E","latestVersionIndicator":"Yes","beginDate":"2010-01-27","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-01-27","modifiedBy":"ONEDATA","dateModified":"2010-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7067841","version":"1","preferredName":"Disease or Disorder Best Response Outcome","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Having the most positive qualities.:Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.:The result of an action.","longName":"C2991:C25432:CS050764:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"CS050764","definition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98434D99-878F-04A4-E053-F662850A7658","latestVersionIndicator":"Yes","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"ONEDATA","dateModified":"2019-11-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98434D99-87A0-04A4-E053-F662850A7658","latestVersionIndicator":"Yes","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeDescription":"11/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7067849","version":"1","preferredName":"Amyloidosis  Status","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._Pertaining to or related to the blood and blood-forming organs._A condition or state at a particular time.","longName":"7067849v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stable Disease (SD)","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98446708-5BFE-633E-E053-F662850A28CC","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"ONEDATA","dateModified":"2019-11-26","deletedIndicator":"No"},{"value":"Progressive Disease (PD)","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98446708-5C08-633E-E053-F662850A28CC","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"ONEDATA","dateModified":"2019-11-26","deletedIndicator":"No"},{"value":"Partial Response (PR)","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3951935","version":"1","preferredName":"Partial Remission","longName":"3951935","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5B7-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98446708-5C13-633E-E053-F662850A28CC","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"ONEDATA","dateModified":"2019-11-26","deletedIndicator":"No"},{"value":"Complete Response (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"98446708-5C1E-633E-E053-F662850A28CC","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"ONEDATA","dateModified":"2019-11-26","deletedIndicator":"No"},{"value":"Very good partial response (VGPR)","valueDescription":"Very good partial response","ValueMeaning":{"publicId":"6757624","version":"1","preferredName":"Very good partial response","longName":"6757624","preferredDefinition":"Reduction in the dFLC (difference between involved serum free light and uninvolved serum free light chain) to < 40 mg/l","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89000172-AE6A-29F8-E053-F662850AB9E0","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"984320C5-8475-04A8-E053-F662850ACC81","beginDate":"2019-05-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"ONEDATA","dateModified":"2019-11-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7067848","version":"1","preferredName":"Amyloidosis Status","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.:A condition or state at a particular time.","longName":"C2868:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"984320C5-8404-04A8-E053-F662850ACC81","latestVersionIndicator":"Yes","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"ONEDATA","dateModified":"2019-11-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"984320C5-8415-04A8-E053-F662850ACC81","latestVersionIndicator":"Yes","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeDescription":"11/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Amyloidosis Best Response","type":"Preferred Question Text","description":"Amyloidosis Best Response","url":null,"context":"NCIP"}],"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9843C9DE-836C-049C-E053-F662850A0B91","latestVersionIndicator":"Yes","beginDate":"2019-11-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-26","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeDescription":"11/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}